Literature DB >> 35776323

Enhanced Transduction of P2X7-Expressing Cells with Recombinant rAAV Vectors.

Anna Marei Mann1, Waldemar Schäfer1, Sahil Adriouch2, Kathleen Börner3,4, Dirk Grimm3,4,5, Ingke Braren6, Friedrich Koch-Nolte7.   

Abstract

Adeno-associated viruses (AAV) are useful vectors for transducing cells in vitro and in vivo. Targeting of specific cell subsets with AAV is limited by the broad tropism of AAV serotypes. Nanobodies are single immunoglobulin variable domains from heavy chain antibodies that naturally occur in camelids. Their small size and high solubility allow easy reformatting into fusion proteins. In this chapter we provide protocols for inserting a P2X7-specific nanobody into a surface loop of the VP1 capsid protein of AAV2. Such nanobody-displaying recombinant AAV allow 50- to 500-fold stronger transduction of P2X7-expressing cells than the parental AAV. We provide protocols for monitoring the transduction of P2X7-expressing cells by nanobody-displaying rAAV by flow cytometry and fluorescence microscopy.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  AAV; Adeno-associated viral vectors; Flow cytometry; Fluorescence microscopy; P2X7; Western blot

Mesh:

Substances:

Year:  2022        PMID: 35776323     DOI: 10.1007/978-1-0716-2384-8_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

1.  Design and construction of functional AAV vectors.

Authors:  John T Gray; Serge Zolotukhin
Journal:  Methods Mol Biol       Date:  2011

2.  Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20.

Authors:  Dustin M McCraw; Jason K O'Donnell; Kenneth A Taylor; Scott M Stagg; Michael S Chapman
Journal:  Virology       Date:  2012-06-09       Impact factor: 3.616

3.  Production of chimeric heavy-chain antibodies.

Authors:  Jianbing Zhang; Roger MacKenzie; Yves Durocher
Journal:  Methods Mol Biol       Date:  2009

4.  Engineering adeno-associated virus serotype 2-based targeting vectors using a new insertion site-position 453-and single point mutations.

Authors:  Jorge Boucas; Kerstin Lux; Anke Huber; Stephanie Schievenbusch; Miriam John von Freyend; Luca Perabo; Sibille Quadt-Humme; Margarete Odenthal; Michael Hallek; Hildegard Büning
Journal:  J Gene Med       Date:  2009-12       Impact factor: 4.565

5.  Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

Review 6.  Engineering adeno-associated viruses for clinical gene therapy.

Authors:  Melissa A Kotterman; David V Schaffer
Journal:  Nat Rev Genet       Date:  2014-05-20       Impact factor: 53.242

7.  Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation.

Authors:  Welbeck Danquah; Catherine Meyer-Schwesinger; Björn Rissiek; Carolina Pinto; Arnau Serracant-Prat; Miriam Amadi; Domenica Iacenda; Jan-Hendrik Knop; Anna Hammel; Philine Bergmann; Nicole Schwarz; Joana Assunção; Wendy Rotthier; Friedrich Haag; Eva Tolosa; Peter Bannas; Eric Boué-Grabot; Tim Magnus; Toon Laeremans; Catelijne Stortelers; Friedrich Koch-Nolte
Journal:  Sci Transl Med       Date:  2016-11-23       Impact factor: 17.956

8.  Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection.

Authors:  C E Wobus; B Hügle-Dörr; A Girod; G Petersen; M Hallek; J A Kleinschmidt
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Identification of a heparin-binding motif on adeno-associated virus type 2 capsids.

Authors:  A Kern; K Schmidt; C Leder; O J Müller; C E Wobus; K Bettinger; C W Von der Lieth; J A King; J A Kleinschmidt
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Naturally occurring antibodies devoid of light chains.

Authors:  C Hamers-Casterman; T Atarhouch; S Muyldermans; G Robinson; C Hamers; E B Songa; N Bendahman; R Hamers
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.